Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 987 across all filing types
Latest filing 2013-03-20 Capital/Financing Update
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed pursuant to the Securities Exchange Act of 1934. It reports a private placement of common stock shares by OvaScience, Inc., including details of the transaction and gross proceeds. The document is not a full financial report but an update on a financing event. The presence of a prospectus supplement and the description of a private placement transaction indicate this is a capital raising activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 4673 characters, which is sufficient to contain substantive information about the financing event, not just an announcement or a brief notice.
2013-03-20 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 19, 2013. It reports the consummation of a private placement of common stock resulting in approximately $35 million in gross proceeds. The content focuses on a financing event rather than financial results, management changes, or other report types. The document length is 2429 characters, which is relatively short but contains substantive information about a capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP).
2013-03-19 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed by OvaScience, Inc. It details a private placement of common stock shares, including a securities purchase agreement and registration rights agreement. The content focuses on a capital raising transaction, describing the terms of the private placement, the investors involved, placement agents, and related agreements. There are no financial statements or comprehensive financial performance data included, nor is this an earnings release or annual/interim report. The document is not a proxy statement, governance report, or legal proceeding update. It is clearly an update on financing activity and capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed transaction terms, supporting a high confidence in classification.
2013-03-14 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 14, 2013. It reports the entry into a material definitive agreement involving a private placement of common stock shares, including details about the securities purchase agreement, registration rights agreement, and related financial terms. The content focuses on a financing transaction and capital raising activity. There are no financial statements or comprehensive financial performance data included, nor is it an earnings release or management discussion. The primary subject is the update on the company's capital structure through a private placement. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is 8714 characters, which is substantive and not merely an announcement or a brief notice, supporting classification as CAP rather than RPA or RNS.
2013-03-14 English
FORM 4 -
Director's Dealing
2013-03-11 English
Regulatory Filings 2013
Regulatory Filings
2013-03-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.